The 42 references in paper A. Sinopalnikov I., Yu. Belotserkovskaya G., А. Синопальников И., Ю. Белоцерковская Г. (2014) “Как улучшить контроль над бронхиальной астмой без увеличения объема базисной терапии? // How can we improve asthma control without escalating therapy?” / spz:neicon:pulmonology:y:2013:i:1:p:77

1
Global Strategy for Asthma Management and Prevention (GINA). Updated 2011. Available onwww.ginasthma.org
(check this in PDF content)
2
Global Initiative for Obstructive Lung Disease (GOLD). Revised 2011. Availlable on www.goldcopd.org
(check this in PDF content)
3
Giraud V., Allaert F.A., Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharma$ cists. Respir. Med. 2011; 105 (12): 1815–1822.
(check this in PDF content)
4
Brocklebank D., Ram F., Wright J. et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the litera$ ture. Hlth Technol. Assess 2001; 5: 1–149.
(check this in PDF content)
5
Dolovich M.B., Ahrens R.C., Hess D.R. et al.Device selec$ tion and outcomes of aerosol therapy: evidence$based guidelines: American College of Chest Physicians / Ameri$ can College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–371.
(check this in PDF content)
6
Molimard M., Raherison C., Lignot M. et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol. Med. 2003; 16: 249–254.
(check this in PDF content)
7
Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.
(check this in PDF content)
8
Melani A.S., Bonavia M., Cilenti V. et al.Inhaler mishan$ dling remains common in real life and associated with reduced disease control. Respir. Med. 2011; 105: 930–938.
(check this in PDF content)
9
Kobrich R., Rudolf G., Stahlhofen W.A mathematical model of mass deposition in man. Ann. Occup. Hyg. 1994; 38: 15–23.
(check this in PDF content)
10
Pauwels R., Newman S., Borgstrom L. Airway deposition and the airway effects of antiasthma drugs delivered from metered$dose inhalers. Eur. Respir. J. 1997; 10: 2127–2138.
(check this in PDF content)
11
Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37: 1308–1331.
(check this in PDF content)
12
Hendeles L., Colice G.L., Meyer R.J.Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N. Engl. J. Med. 2007; 356: 1344–1351.
(check this in PDF content)
13
Thorsson L., Edsbacker S. Lung deposition of budesonide from a pressurized metered$dose inhaler attached to a spac$ er. Eur. Respir. J. 1998; 12: 1340–1345.
(check this in PDF content)
14
Ganderton D.Targeted delivery of inhaled drugs: current challenges and future goal. J. Aerosol. Med. 1999; 12 (Suppl. 1): S3–S8.
(check this in PDF content)
15
Scichilone N., Spatofora M., Battaglia S. et al.Lung penetra$ tion and patient adherence considerations in the manage$ ment of asthma: role of extra$fine formulations. J. Asthma and Allergy 2013; 6: 11–21.
(check this in PDF content)
16
Leach C.L., Kuehl P.J., Chand R. et al.Characterization of respiratory deposition of fluticasone$salmeterol hydrofluo$ roalkane$134a and hydrofluoroalkane$134a beclometha$ sone in asthmatic patients. Ann. Allergy Asthma Immunol. 2012; 108 (3): 195–200.
(check this in PDF content)
17
Mariotti F., Poli G., Acerbi D. et al. 2007 Lung deposition of BDP / formoterol HFA pMDI in healthy volunteers, asth$ matic and COPD patients [abstract]. Poster presented at the VIII UIP National congress, Florence, 4–7 December 2007.
(check this in PDF content)
18
Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 2007; 120: 1269–1275.
(check this in PDF content)
19
Scichilone N., Battaglia S., Olivieri D., Bellia V.The role of small airways in monitoring the response to asthma treat$ ment: what is beyond FEV1? Allergy 2009; 64: 1563–1569.
(check this in PDF content)
20
Frey U., Suki B.Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assess$ ment, and disease progression and control. Lancet 2008; 372: 1088–1099.
(check this in PDF content)
21
Beigelman2Aubry C., Capderou A., Grenier P.A. et al. Mild intermittent asthma: CT assessment of bronchial cross$sec$ tional area and lung attenuation at controlled lung volume. Radiology 2002; 223: 181–187.
(check this in PDF content)
22
Ueda T., Niimi A., Matsumoto H. et al. Role of small airways in asthma: investigation using high$resolution computed tomography. J. Allergy Clin. Immunol. 2006; 118: 1019–1025.
(check this in PDF content)
23
Bourdin A., Paganin F., Prefaut C. et al. Nitrogen washout slope in poorly controlled asthma. Allergy 2006; 61: 85–89.
(check this in PDF content)
24
Battaglia S., den Hertog H., Timmers M.C. et al. Small air$ ways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60: 639–644.
(check this in PDF content)
25
Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Incre$ ased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur. Respir. J. 2002; 20: 841–845.
(check this in PDF content)
26
Berry M., Hargadon B., Morgan A. et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J. 2005; 25: 986–991.
(check this in PDF content)
27
Yixin S., Aledia A.S., Tatavoosian A.V. et al.Relating small airways to asthma control by using impulse oscillometry in children. J. Allergy Clin. Immunol. 2012; 129: 671–678.
(check this in PDF content)
28
Yanai M., Sekizawa K., Ohrui T. et al. Site of airway obstruc$ tion in pulmonary disease: direct measurement of intra$ bronchial pressure. J. Appl. Physiol. 1992; 72: 1016–1023.
(check this in PDF content)
29
Contoli M., Kraft M., Hamid Q. et al. Do small airway abnor$ malities characterize asthma phenotypes? In search of proof. Clin. Exp. Allergy 2012; 42: 1150–1160.
(check this in PDF content)
30
Global Strategy for Asthma Management and Prevention (GINA). Updated 2011. Available on www.ginasthma.org
(check this in PDF content)
31
Bateman E.D., Boushey H.A., Bousquet J. et al. Can guide$ line$defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844
(check this in PDF content)
32
Greening A.P., Ind P.W., Northfield M. et al.Added salme$ terol versus higher$dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224.
(check this in PDF content)
33
Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405–1411.
(check this in PDF content)
34
Papi A., Paggiaro P., Nicolini G. et al.Beclomethasone / for$ moterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62 (10): 1182–1188.
(check this in PDF content)
35
Huchon G., Magnussen H., Chuchalin A. et al.Lung function and asthma control with beclometha$ sone and formoterol in a single inhaler. Respir. Med. 2009; 103 (1): 41–49.
(check this in PDF content)
36
Scichilone N., Battaglia S., Sorino C. et al.Effects of extra$ fine inhaled beclomethasone / formoterol on both large and small airways in asthma. Allergy 2010; 65 (7): 897–902.
(check this in PDF content)
37
Muller V., Galffy G., Eszes N. et al.Asthma control in patients receiving inhaled corticosteroid and long$acting beta2$agonist fixed combinations. A real$life study comparing dry powder inhalers and a pressurized metered dose inhaler extra$fine formulation. BMC Pulm. Med. 2011; 11: 40.
(check this in PDF content)
38
Allegra L., Cremonesi G., Girbino G. et al. Real$life prospec$ tive study on asthma control in Italy: cross$sectional phase results. Respir. Med. 2012; 106 (2): 205–214.
(check this in PDF content)
39
Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone / formoterol versus budesonide / formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29 (4): 682–689.
(check this in PDF content)
40
Papi A., Nicolini G., Crimi N. et al. Step$down from high dose fixed combination therapy in asthma patients: a ran$ domized controlled trial. Respir. Res. 2012; 13: 54.
(check this in PDF content)
41
Goldin J.G., Tashkin D.P., Kleerup E.C. et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipro$ pionate inhalation on small airways: assessment with functional helical thin$section computed tomography. J. Allergy Clin. Immunol. 1999; 104 (6): S258– S267.
(check this in PDF content)
42
Terzano С., Cremonesi G., Girbino G. et al.1$year prospec$ tive real life monitoring of asthma control and quality of life in Italy. Respir. Res. 2012, 13: 112–123. Информация об авторах Синопальников Александр Игоревич– д. м. н., проф., зав. кафедрой
(check this in PDF content)